Navigation Links
Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
Date:10/29/2009

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's Web site: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intelle
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
2. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
3. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
4. Veriscrip and DAMMAD Team Up to Combat Prescription Drug Abuse in New Hampshire
5. New Hampshire Rx Card Launching Statewide
6. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
7. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
8. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
9. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/1/2014)... companies EBI, LLC, of New Jersey , and ... pay the United States $6.07 million to ... the companies, bone growth stimulators. The settlement this week ... Biomet, Yue Yu, pursuant to the qui tam provisions ... , LLP, a Philadelphia -based personal injury law ...
(Date:11/1/2014)... Wash. , Oct. 31, 2014 Talyst, ... at the 2014 American Society of Consultant Pharmacists (ASCP) ... The meeting and expo will bring together pharmacists and ... the latest technologies. In recent years, ... focus for LTC pharmacies. The InSite® System, Talyst,s LTC ...
(Date:11/1/2014)... and CHICAGO , Oct. 31, 2014 ... Durata Therapeutics, Inc. (NASDAQ: DRTX ) today ... granted early termination of the waiting period under the ... to Actavis, pending acquisition of Durata. Logo ... termination of the HSR waiting period satisfies one of ...
Breaking Medicine Technology:Biomet to Pay Over $6 Million to Resolve Whistleblower Claims That It Paid Kickbacks to Doctors 2Talyst Exhibits at ASCP Annual Meeting 2Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 2Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 3Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 5Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 6
... 2011 As part of a nationwide effort to prevent ... supporting National Prescription Drug Take-Back Day, which is ... on Saturday, October 29. "Unused prescription medicines that ... are not handled properly," said Paul Kaplan, M.D., BCBSD Vice ...
... information from a recent proprietary study affirming that seeing is ... seeing was an overwhelming choice, selected by 10 times as ... "This research affirms how important seeing is to people and ... VisionSpring President. "With over 700 million people in the world ...
Cached Medicine Technology:Blue Cross Blue Shield of Delaware Supports the Drug Enforcement Administration's "National Prescription Drug Take-Back Day" 2VisionSpring Research Finds Seeing to be the Most Important of Five Senses 2
(Date:10/31/2014)... 31, 2014 This Method to ... health effects for practitioners. , The Hypopresive ... of Science and Movement specializing in physical rehabilitation. ... pelvic floor reeducation that traditional abdominal exercises after ... Recti, Prolepses, etc. , The Hipopressives exercises pull ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Energy Textiles ... gear. The new gear is now available online, and ... the benefits of Celliant infrared-active athletic gear over compression ... that another contract has been signed for Under Armour ... for the next eight years. In light of this ...
(Date:10/31/2014)... (HealthDay News) -- Sleep apnea may make it hard for ... your car or left your house keys, a small study ... showed that this ability -- called spatial memory -- was ... even when other stages of sleep weren,t affected. REM sleep ... occur. "We,ve shown for the first time that sleep ...
(Date:10/31/2014)... of duration of treatment and cost, patients with ... partial breast irradiation (APBI) with proton therapy versus ... from The University of Texas MD Anderson Proton ... analysis study based on typical patient characteristics, researchers ... for eight different types of partial and whole ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3
... ... censorship of independent media and web sites, including information on mind-body healing, meditation, yoga, and ... ... ranks of more than five million Internet sites banned by the Iranian government since 2008. ...
... , Health Professions Scholarship Program (HPSP) Supports Students Pursuing ... FORT KNOX, Ky., June 22 The U.S. Army ... stipend associated with its Health Professions Scholarship Program (HPSP) ... this economic downturn, many medical and dental students are ...
... Call Today at 9:00am ET , , Covers ... , , Includes Licensing Option ... MATEO, Calif. and STAINES, England, June 22 NeurogesX, Inc. (Nasdaq: ... of Tokyo based Astellas Pharma Inc. announced today that the companies have ...
... & Me"(C) Checklist to Help Patients Organize Vital ... , LifelinetoModernMedicine.com Provides Patients with Physician-Certified Tools and ... Every year, 46 million Americans face the ... educate and inform prospective patients and the public ...
... Taiwan, June 22 /PRNewswire-Asia/ -- The Healthcare & ... of a Memorandum of,Understanding (MOU) with the Science ... non-profit organization under the National,Applied Research Laboratories in ... for Taiwan,s Science & Technology (S&T) development. , ...
... ... , ... ICM Controls, a leader in the manufacture and supply of electronic controls to the HVACR ... Speed Control that promotes effective Humidity Control in residential and small commercial ...
Cached Medicine News:Health News:Iran Blocks Access to the Chopra Center's Web Site, Podcasts, and Blogs 2Health News:Iran Blocks Access to the Chopra Center's Web Site, Podcasts, and Blogs 3Health News:U.S. Army Increases Medical and Dental School Benefits 2Health News:U.S. Army Increases Medical and Dental School Benefits 3Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 2Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 3Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 4Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 5Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 6Health News:American Society of Anesthesiologists Launches Web Site Focused on Educating and Empowering the Public about Anesthesiology 2Health News:American Society of Anesthesiologists Launches Web Site Focused on Educating and Empowering the Public about Anesthesiology 3Health News:Taiwan's Science & Technology Policy Research and Information Center (STPI) and Thomson Reuters Sign MOU of Collaboration to Support Science & Technology Development 2Health News:Taiwan's Science & Technology Policy Research and Information Center (STPI) and Thomson Reuters Sign MOU of Collaboration to Support Science & Technology Development 3Health News:ICM Controls' Award-Winning Comfort Control Center Improves Comfort and Indoor Air Quality While Lowering Energy Costs 2Health News:ICM Controls' Award-Winning Comfort Control Center Improves Comfort and Indoor Air Quality While Lowering Energy Costs 3
Acuvue Toric is an exceptionally comfortable soft contact lens made especially for people with astigmatism. The Acuvue Toric lens is designed to comfortably fit the unique shape of your eye....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
... Vitrasert implant is a device that ... Aids-related Cytomegalovirus (CMV) Retinitis. This approach ... when compared with conventional intravenous treatment. ... in a polymer-based system that slowly ...
Near PT test card/illus of the ocular adnexa 5 1/2" X 8"....
Medicine Products: